{
    "nct_id": "NCT06261060",
    "official_title": "Low-Dose Sirolimus to Increase Hematopoietic Function in Patients With RUNX1 Familial Platelet Disorder",
    "inclusion_criteria": "* Participants has provided signed, informed consent before initiation of any study specific procedures\n* Aged ≥18 years at the time of signing the informed consent\n* Confirmed P/LP germline RUNX1 variant per ClinGen Myeloid Malignancy Variant Curation Expert Panel (MM-VCEP) RUNX1-specific variant curation rules80\n* Participants must be willing to provide bone marrow sample at time of screening and at the end of treatment with sirolimus\n* Platelet count of ≥50,000/µL\n* Adequate renal function: estimated glomerular filtration rate based on Modification of Diet in Renal Disease (MDRD) calculation, >30 mL/min/1.73m2\n* Adequate hepatic function: aspartate aminotransferase (AST) and alanine aminotransferase (ALT) <3 × upper limit of normal (ULN) and total bilirubin <1.5 × ULN\n* Adequate cardiac function: left ventricular ejection fraction >50%\nHealthy volunteers allowed\nMust have minimum age of 18 Years",
    "exclusion_criteria": "* Known allergy to sirolimus\n* History of lymphoma or other hematologic malignancies\n* Uncontrolled bleeding\n* Any prior diagnosis of myelodysplastic syndrome or other hematologic malignancy using International Working Group criteria\n* Prior treatment with sirolimus or a rapalog, mTOR inhibitor, or B-cell-depleting therapy within 28 days before study day 1\n* Treatment with strong inhibitors of cytochrome P450 3A4 (CYP3A4; eg, ketoconazole, voriconazole, itraconazole, erythromycin, telithromycin, and clarithromycin), strong inducers of CYP3A4 (eg, rifampin and rifabutin), other drugs that could increase sirolimus blood concentrations (eg, bromocriptine, cimetidine, cisapride, clotrimazole, danazol, diltiazem, fluconazole, letermovir, protease inhibitors [eg, ritonavir, indinavir, boceprevir, and telaprevir], metoclopramide, nicardipine, troleandomycin, and verapamil), other drugs that could decrease sirolimus blood concentrations (eg, carbamazepine, phenobarbital, phenytoin, rifapentine, St. John's Wort [Hypericum perforatum]), or drugs with blood concentrations that could increase (eg, verapamil) within 7 days before study day 1\n* Use of cannabidiol, which can increase blood levels of sirolimus, within 7 days before study day 1\n* Myocardial infarction within 6 months before study day 1, congestive heart failure (New York Heart Association > class II)\n* Total cholesterol >300 mg/dL or triglyceride >400 mg/dL\n* Arterial thrombosis (eg, stroke or transient ischemic attack) within 6 months before study day 1\n* Infection requiring intravenous anti-infective treatment within 1 week of study day 1\n* Live vaccines (eg, measles, mumps, rubella, oral polio, BCG, yellow fever, varicella, and TY21a typhoid) within 28 days before study day 1\n* Known diagnosis of chronic viral infection (eg, hepatitis B or C or HIV, and Epstein-Barr) or tuberculosis\n* Women who are pregnant, may become pregnant, or who are breastfeeding",
    "miscellaneous_criteria": ""
}